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T
he recent development of 
human induced pluripotent 
stem (iPS) cells [1–5] has 
reshaped the scientific and political 
landscape of stem cell biology. iPS cells 
provide an unprecedented opportunity 
to study the pathophysiology of 
diseases, understand stem cell biology, 
identify new therapeutic targets, and 
test new therapies. Furthermore, they 
offer the possibility of transplanting 
therapeutic cells that are genetically 
identical to their recipient. 
iPS cells are not included in the 
heated debates over the ethics of 
embryonic stem cell research because 
embryos or oocytes are not used. The 
President’s Council on Bioethics called 
iPS cells “ethically unproblematic and 
acceptable for use in humans” [6]. 
Currently, there are no restrictions on 
federal funding of iPS cell research, 
and iPS cells are not subject to the 
special regulations in place for 
embryonic stem cells [7]. While neither 
the donation of materials to derive 
iPS cells nor their derivation raises 
special ethical issues, some potential 
downstream uses of iPS derivatives may 
be so sensitive as to call into question 
whether the original somatic cell 
donors would have agreed to such uses. 
In light of the enormous scientific and 
public interest in iPS cells and claims 
about their lack of ethical problems, 
it is important to consider these 
downstream issues now. Although these 
concerns also apply to other types of 
stem cell and genomics research, they 
are particularly salient to iPS research 
for two reasons. First, if the perception 
that iPS research poses no ethical 
concerns is not corrected, there could 
be a backlash against iPS cells later. 
Second, the virtual genetic identity 
between iPS cells and donor cells raises 
particular concerns regarding respect 
for donors. 
Because human biological materials 
are precious and iPS cells can be 
propagated indefinitely, it is advisable 
to design the consent process for 
donating somatic cells for iPS 
derivation to facilitate a broad range 
of future research, beyond what the 
initial investigators may have in mind. 
The US National Academy of Sciences 
recently revised its guidelines for stem 
cell research [7]. In this paper, we 
go beyond the National Academy of 
Sciences report to recommend how 
the consent process for the donation 
of somatic cells to derive iPS cell lines 
should foster their future scientific 
uses, particularly in fundamental 
research to study the properties of 
stem cells, derive specialized cells, 
and carry out preclinical studies of 
transplantation.
Consent for Derivation of Human 
iPS Cells
The research groups that first 
reported the derivation of human 
iPS cells used commercially available 
“de-identified” human somatic cells 
[2–4,8]. Using previously collected 
cells may be advantageous if they are 
well characterized and scientists have 
extensive experience growing them and 
working with them. 
Generally, informed and voluntary 
consent in research is required to 
fulfill the ethical principle of respect 
for persons. This requirement 
is identified as fundamental in 
international standards, such as the 
Helsinki Declaration and the Council 
for International Organizations of 
Medical Sciences’ “International 
Ethical Guidelines for Biomedical 
Research Involving Human Subjects,” 
in good clinical practice standards, in 
US regulations for the protection of 
human research participants [9–14], 
and in stem-cell-specific standards from 
the International Society for Stem Cell 
Research, the US National Academy of 
Sciences, and the California Institute 
for Regenerative Medicine [15–17]. 
Under US regulations for research 
on humans, an exception to consent 
allows existing biological materials to 
be used for research without consent 
if they are de-identified. The rationale 
for this exception is that there is no 
risk of physical harm to donors, and 
de-identifying materials greatly reduces 
the risk of breaches of confidentiality. 
However, use of de-identified samples 
raises concerns about confidentiality 
and the possibility that donors might 
not approve of certain downstream 
research uses. Existing biological 
materials may also be used for research 
if the donor has consented, which 
may be simply a general consent to 
research. These policies regarding 
research with existing biological 
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materials enjoy widespread but not 
unanimous public support. A 2006 
paper reviewed 30 papers on attitudes 
toward consent for research with 
human biological samples [18]. Of 
20 studies that surveyed willingness to 
donate tissues, 17 reported that over 
80% of respondents said they would 
donate a sample if asked. Furthermore, 
in six studies that addressed the issue, 
79%–95% of respondents were willing 
to provide one-time general consent 
and to allow ethics committees to 
determine the studies for which their 
samples would be used. None of the 
reviewed studies, however, addressed 
stem cell research or informed 
respondents about potentially sensitive 
research that might be carried out 
using their specimens. 
A great advantage of iPS cells is that 
they can be derived from a person 
carrying a specific gene mutation or 
having a specific disease or condition, 
thereby creating an in vitro model for 
human diseases. Thus, many new iPS 
cell lines will be created from newly 
donated biological materials [8]. 
Future Fundamental Research with 
iPS Cells
Wide sharing of iPS lines will facilitate 
progress in this exciting field. It will 
be impossible to predict whether an 
individual iPS line will be particularly 
well suited for specific functions, such 
as deriving therapeutic cell types or 
screening drug responses. Future 
researchers will likely want to carry out 
a broad range of basic experiments 
with iPS cells and derivatives, using 
common and well-accepted scientific 
practices (Box 1).
These standard research techniques 
are widely used in other types of 
basic research and provide important 
scientific information. Large-scale 
genome sequencing is likely to yield 
new insights about the pathogenesis 
of disease and to identify new 
targets for therapy. Injection of 
human stem cells into the brains of 
nonhuman animals will be required 
for preclinical testing of cell-based 
therapies for many conditions, such 
as Parkinson disease, Alzheimer 
disease, and stroke. Generally, 
donors of biological materials are not 
explicitly informed of these research 
procedures, although such disclosure 
is now proposed for whole-genome 
sequencing [20,21]. 
However, this research could 
raise concerns. For example, large-
scale genome sequencing may 
evoke concerns about privacy and 
confidentiality. Donors might consider 
their privacy violated if scientists 
know their future susceptibility to 
many genetic diseases. Furthermore, 
re-identification of the donor of a de-
identified large-scale genome sequence 
might be possible if confidentiality is 
breached at forensic DNA databases or 
an Internet company offering personal 
genomic testing [22,23]. 
Other donors may object to their 
cells being injected into animals. For 
example, they may oppose all animal 
research, or they may have religious 
objections to the mixing of human 
and animal species. The injection of 
human neural progenitor cells into 
nonhuman animals has raised ethical 
concerns about animals developing 
characteristics considered uniquely 
human [24,25]. Transplanted cells are 
influenced by the microenvironment 
in the recipient [26,27], and human 
neural progenitor cells have been 
transplanted into developing animal 
brains without observed behavioral 
alterations [28]. However, we do 
not know exactly what behavioral 
components to look for or how to 
measure mental capacities in animals. 
The possibility of creating a more 
human-like animal may be greater if 
most of the animal brain cells at the 
early stage of development are replaced 
in a primate species closely related to 
humans.
We note that these ethical concerns 
are not unique to iPS research. They 
apply to other stem cell research and 
to large-scale genomic sequencing. 
These ethical concerns may be resolved 
if somatic cell donors give consent for 
derivatives of their cells to be used in 
such research. Later in the paper, we 
discuss how such consent for future 
research may be obtained. 
Future Sensitive Research with iPS 
Cells
Two types of future research with iPS 
cells—transplantation and reproductive 
research—are likely to be particularly 
controversial, both because many 
somatic cell donors can be predicted 
to disapprove of them and because 
explicit consent is generally required 
for these activities in other settings. 
Human transplantation of iPS cells is 
not feasible in humans with current 
techniques of inducing pluripotency 
that require integration of foreign 
DNA. However, it is widely anticipated 
that “integration-free” iPS cells will 
be developed in the next few years, 
making human transplantation 
possible.
Transplantation into humans. For 
transplantation of solid organs, tissues, 
or allogenic cord blood, expressed 
consent is required from donors or 
their surrogates. Transplantation of 
cells derived from iPS cells would differ 
from organ and tissue transplantation 
because obtaining tissue for iPS cells 
is minimally invasive. However, some 
people may not want their cells to 
become an integral, growing part of 
another person. While many people 
are eager to give the “gift of life,” 
others choose not to donate organs 
[29]. “Presumed” consent for cadaveric 
transplantation has scant support 
in the US [30]. Prior consent for 
unspecified research would not resolve 
the problem, because donors may 
not have considered the possibility of 
transplantation when providing somatic 
cells. De-identifying donor cells also 
does not eliminate their objections. 
Thus, respecting donor autonomy 
would require explicit consent for stem 
cell transplantation. 
An additional reason for obtaining 
explicit consent for allogenic 
transplantation is the safety of 
transplant recipients. The interval 
between the original donation of 
the somatic cells and the proposed 
stem cell transplantation might be 
many years. If the donor developed 
cancer, or if a strong family history 
of cancer was recognized during this 
time, the risks to recipients might be 
Box 1. Future Basic Research 
Uses of iPS Cells 
sÈ 'ENETICÈMODIFICATIONÈOFÈCELLS
sÈ )NJECTIONÈOFÈI03ÈCELLSÈORÈDERIVATIVESÈINTOÈ
nonhuman animals, including injection 
into the brain
sÈ ,ARGE
SCALEÈGENOMEÈSEQUENCING
sÈ 3HARINGÈCELLÈLINESÈWITHÈOTHERÈ
researchers, with appropriate 
confidentiality protections
sÈ 0ATENTINGÈSCIENTIFICÈDISCOVERIESÈANDÈ
developing commercial tests and 
therapies, with no sharing of royalties 
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increased. Screening the materials to 
be transplanted (e.g., for karyotype 
abnormalities or for alleles strongly 
associated with cancer) would fail 
to identify some risks to recipients, 
because the genetic basis of many 
inherited cancers has not been 
identified. The importance of careful 
screening of iPS cells is magnified 
by the fact that these cells can be 
propagated for many passages, and 
many patients may receive stem cell 
transplants from a single donor. 
Banks of just a few hundred carefully 
selected stem cells might serve the 
transplant needs of a large portion 
of the population. Thus, it would be 
desirable to periodically obtain an 
updated medical and family history 
from the donor of a somatic cell 
line that is being used for repeated 
transplantations. Recontacting donors 
without their prior permission, 
however, might be considered an 
invasion of privacy. Hence, consent for 
recontact should be obtained when the 
somatic cells are donated and approved 
by the institution’s internal review 
board (IRB) or stem cell research 
oversight (SCRO) committee. 
Reproductive research. Human iPS 
cells might be made to differentiate 
into primordial germ cells and then 
into mature gametes [31]. Gametes 
derived from iPS cells would be useful 
both for understanding gametogenesis 
and as a potential infertility treatment 
[31]. Gametes derived from iPS cells 
would have virtually the same DNA as 
the somatic cell donor. 
Basic research on gamete 
maturation raises few ethical concerns. 
Studying how gametes develop is 
similar to studying how neural cells, 
cardiomyocytes, and beta islet cells 
develop. However, using gametes 
derived from iPS cells for research 
on reproduction may raise serious 
ethical objections because of the moral 
significance of reproduction and strong 
disagreements over the moral status of 
embryos [32–34]. Furthermore, if iPS 
cells are actually totipotent and could 
potentially be used for reproductive 
cloning, additional strong moral 
objections are likely to develop [32,35]. 
Many Americans—as many as 
62% in some opinion polls—believe 
that embryos should not be created 
specifically for research purposes 
[36]. However, some somatic cell 
donors would welcome research to 
create embryos with gametes derived 
from iPS cells because it might lead to 
breakthroughs in infertility treatment. 
On the other hand, some people can 
be expected to object to using such 
gametes for reproductive research 
involving fertilization, parthenogenesis, 
or androgenesis. For example, some 
people strongly believe that embryos 
should only be created through 
sexual intercourse and that in vitro 
fertilization violates natural law and 
divine commandment [33]. These 
individuals would object to such 
reproductive research using gametes 
derived from their somatic cells, as well 
as carrying out reproductive research 
without specific consent from somatic 
cell donors. De-identifying the iPS 
derivatives would not overcome their 
opposition.
Thus, explicit, separate consent 
from donors of somatic cells should be 
required for reproductive research that 
attempts to create totipotent cells from 
gametes derived from iPS derivatives. 
In light of the objections raised to 
reproductive cloning [32,35], we 
believe that research for this purpose 
should be prohibited. 
Suggested Informed Consent 
Procedures
No one can predict if an iPS line being 
derived will become highly desirable 
for use in future research (e.g., because 
it grows robustly in culture). When 
researchers obtain somatic cells to 
derive new iPS lines, they should also 
ask donors for permission to carry 
out additional basic research that 
will be needed to reap the hoped-for 
scientific benefits of these remarkable 
cells. Flawed consent for the donation 
of materials to derive human stem 
cell lines has called into question 
downstream uses of the lines [7,37]. 
There are conflicting ethical and 
policy considerations regarding future 
research with biological materials. 
On the one hand, researchers must 
respect persons who donate materials 
[12,38,39]. However, it is difficult to 
specify what the level of detail in the 
consent process should be. Exhaustive 
disclosure of the details of research may 
be confusing and counterproductive. 
We contend that participants ought 
to appreciate essential features of the 
project, particularly those pertinent 
to decisions to participate or not 
participate. Unless they are told, donors 
might not realize that some research 
might be considered objectionable to 
a substantial minority of donors; large-
scale genome sequencing has been 
cited as an example [40,41]. Future 
research presents additional challenges 
regarding consent. Blanket consent or 
general consent, in which donors agree 
to all unspecified future studies using 
their materials, may be uninformed if 
donors are not told about the kinds 
of projects that might be considered 
objectionable [42]. 
On the other hand, scientifically 
essential and ethically acceptable 
research should be encouraged for the 
benefit of society and future patients. 
Undue delays and administrative 
burdens on such research should be 
minimized. It would be inefficient for 
scientists to invest time and effort to 
derive a new iPS line with cells from 
a donor who would not agree to basic 
research procedures needed to make 
use of these valuable cell lines. For 
example, the scientific usefulness 
of a line would be compromised if 
the donor would not allow injection 
into animals or large-scale genome 
sequencing.
We recommend that scientists 
use somatic cells only from donors 
who agree to the basic research 
procedures listed in Box 1. During 
the consent process, researchers need 
to help donors understand that these 
techniques are essential to achieve the 
goals of understanding diseases and 
developing new therapies and that 
they are widely used in other types 
of research, such as cancer research. 
Donors should also be invited to ask 
questions. Although these research 
procedures should be discussed with 
the IRB or SCRO committee reviewing 
the protocol, they may not need to be 
discussed with donors of biological 
materials during the consent process. 
It would be administratively simpler 
if widely distributed cell lines could 
be used for all the procedures in Box 
1, rather than imposing different 
restrictions on different lines. There is 
likely to be no shortage of donors for iPS 
research who agree to allow derivatives 
of their cells to be used in this range of 
fundamental research. In rare situations, 
it may be desirable to derive iPS lines 
from donors who do not agree to these 
conditions. For example, a donor with 
a rare condition or mutation that would 
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agree to large-scale genome sequencing 
or injection into animals, even after 
attempts to explain the importance of 
such downstream research. 
As noted, concerns about consent 
for future research with biological 
materials can also be raised about 
other types of research, including 
research with other types of stem 
cells. Researchers may also wish to ask 
donors to agree to the procedures in 
Box 1, to facilitate future studies. 
We further recommend obtaining 
permission to recontact donors in the 
future, subject to IRB approval. The 
ability to recontact donors offers the 
opportunity to discuss future research 
that is so innovative that it cannot be 
anticipated today [43], and that IRBs 
or SCRO committees might consider 
outside the scope of the original 
consent.
Clinical transplantation and 
reproductive research deserve 
special consideration. Some people 
who support the basic iPS research 
listed in Box 1 might object to these 
applications. However, there would 
be little lost in terms of fundamental 
stem cell biology if some somatic 
cell donors excluded their cells from 
transplantation or reproductive 
research. Thus, we suggest a tiered 
consent process. After obtaining 
consent for derivation and the 
procedures in Box 1, researchers 
should routinely ask for additional 
consent to use derived cells for clinical 
transplantation. We believe that 
permission for reproductive research 
should be sought separately and only in 
exceptional cases, when researchers can 
foresee colleagues carrying out such 
work, because some donors will have 
deeply rooted objections. Donors could 
still provide cells for iPS derivation and 
the research listed in Box 1, even if 
they decline these additional uses. 
Our recommendations are intended 
as ethical guidelines, not as regulatory 
guidelines. Many aspects of human stem 
cell research are not, strictly speaking, 
research on humans. Many scientists 
and policy makers were reluctant to 
subject human embryonic stem cell 
research to the federal regulations 
for research on human participants. 
Difficult ethical issues were not covered 
by these regulations, and IRBs as 
currently constituted did not have the 
expertise to address stem-cell-specific 
issues [16]. Currently, iPS cell research 
may be subject to state stem cell 
research regulations. We believe that 
voluntary professional guidelines should 
play a crucial important role at this 
time. As we have argued, on issues such 
as consent for downstream research, 
current federal regulations for research 
on human participants may need to 
be reconsidered. Ethical guidelines 
are more flexible than regulations and 
allow consensus standards to develop 
on emerging issues and be applied 
consistently across different types of 
research. 
In summary, iPS cells are an 
exciting new approach to developing 
pluripotent stem cell lines that are 
genetically identical to people with 
known phenotypes. While they 
avoid the ethical issues inherent in 
embryonic stem cells, they do raise 
some ethical concerns regarding 
consent for future research. Obtaining 
consent for fundamental downstream 
research with iPS cells, together 
with offering the options of allowing 
recontact by researchers and giving 
permission for additional sensitive types 
of future research, will show respect for 
somatic cell donors, promote public 
trust in stem cell research, and allow 
optimal use of scientific discoveries.  
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